Reconstruction xspect

Each patient was injected with [^99mTc]Tc-ADAPT6, followed by injection with [^99mTc]Tc-(HE)₃-G3 after 3–4 days. In patient 1, the interval between injection was 15 days.
The injected protein masses and timing of imaging were selected based on the results of previous Phase I studies [9 (link),10 (link)]. The injected protein masses were 500 and 3000 µg for [^99mTc]Tc-ADAPT6 and [^99mTc]Tc-(HE)₃-G3, respectively. [^99mTc]Tc-ADAPT6 (523 ± 211 MBq) and [^99mTc]Tc-(HE)₃-G3 (443 ± 185 MBq) were injected intravenously. Imaging was performed using a Siemens Symbia Intevo Bold scanner equipped with a high-resolution low-energy collimator. SPECT/CT scans (SPECT: 60 projections, 20 s each, stored in 256 × 256 pixel matrix/CT: 130 kV, effective 36 mAs) were performed 2 h after injection for [^99mTc]Tc-ADAPT6 and 4 h after injection for [^99mTc]Tc-(HE)₃-G3 in all patients. SPECT images were reconstructed using a reconstruction xSPECT (Siemens) protocol based on the ordered subset conjugate gradient (OSCG) method (24 iterations, 2 subsets). The 3D Gaussian FWHM 10 mm filter (Soft Tissue) was used. The images were processed using the proprietary software package Syngo.via (Siemens).

Imaging was performed 2 h after injection of [^99mTc]Tc-ADAPT6 using a Siemens Symbia Intevo Bold scanner with a high-resolution low-energy collimator. In all breast cancer patients, SPECT/CT scans (SPECT: 60 projections of 20 s each; images stored in a 256 × 256 pixel matrix; CT: 130 kV; 36 mAs) of the chest were completed and reconstructed using the reconstruction xSPECT (Siemens) protocol based on the ordered subset conjugate gradient (OSCG) method (24 iterations with 2 subsets). The 3D Gaussian FWHM 10 mm filter (Soft Tissue) was used. The images were processed using the proprietary software (Version 2006A) package Syngo.via Siemens Healthineers, Erlangen, Germany).
Maximum Standard Uptake Values were normalized to the participants’ body weight (SUV_max) and calculated for primary tumours, contralateral symmetric breast regions and mALN and contralateral symmetric lymph node (LN) regions 2 h after injection. Additionally, SUV_max was also calculated for the liver, latissimus dorci muscle (LDM) and spleen for determination of the best tumour-to-reference and mALN-to-reference tissue ratio.